We have gained a strong reputation for creating value through acquisitions and in-licensing activities – getting the most out of leading technologies by investing in further development, regulatory approvals and commercial activities.

BTG welcomes new opportunities for licensing and acquisition.

We typically look for opportunities where we can leverage our existing capabilities; providing innovative products that enable specialist physicians to serve their patients better.

We have a track record of acquisitions and licensing agreements in both Interventional Medicine and Pharmaceuticals.  These assets are sold through our established sales channels or through new sales teams supported by our existing commercial infrastructure.


In all cases we seek to maximise the value of these products by investing in development, regulatory approvals and commercial activities.

If you have a product or technology you believe BTG may be interested in, please send your enquiries to:
Charles Brigden
SVP, Head of Business Development


  • AboutUs_TwoColModules.png

    About Us

    Healthcare is constantly evolving, so BTG never stands still. Inspired by a deep understanding of our customers’ needs, we endeavour to meaningfully improve health outcomes and the patient experience.

    Read more
  • 15 Jun 2016

    BTG plc acquires Galil Medical

    BTG expands its Interventional Oncology franchise with the acquisition of Galil Medical, a leader in cryoablation

    Read more